NCT04322474

Brief Summary

The first Russian registry presents data from two hundred consecutive patients with nonvalvular atrial fibrillation, who undergone left atrial appendage occlusion (LAAO) using the Watchman device and the Amplatzer cardiac plug. This government-funded catheter-based LAAO program was started in September 2015 and was completed in December 2017. Data collection was finished in December 2018. Five clinics agreed to participate in the study. Patients' baseline characteristics, procedure, and follow up data were collected according to established registry protocol. Patients were followed at 45 days, 3, 6 and 12 months after enrollment. At each follow-up visit, the data regarding clinical events and healthcare utilization was collected.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2015

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2015

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2017

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

March 24, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 26, 2020

Completed
Last Updated

March 26, 2020

Status Verified

March 1, 2020

Enrollment Period

2.3 years

First QC Date

March 24, 2020

Last Update Submit

March 25, 2020

Conditions

Keywords

atrial fibrillationleft atrial appendagestroke preventionoccluderWatchman deviceAmplatzer Cardiac Plug

Outcome Measures

Primary Outcomes (2)

  • Procedure-related major adverse events (pericardial effusion, cardiac tamponade, device embolization, procedure/device-related death)

    12 months

  • The composite of thromboembolic events, device thrombosis, hemorrhagic events, unexplained death

    Primary efficacy endpoint

    12 months

Secondary Outcomes (2)

  • Procedure success rate

    intraprocedural

  • Peridevice leakage

    6 months

Interventions

Catheter-based implantation of left atrial appendage occluder

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Nonvalvular atrial fibrillation patients with a high risk of thromboembolic and haemorrhagic events

You may qualify if:

  • age ≥18 years nonvalvular atrial fibrillation,
  • CHA2DS2VASc ≥2,
  • high risk of hemorrhagic events,
  • non-compliance with pharmacological anticoagulant therapy

You may not qualify if:

  • significant mitral valve disease,
  • left ventricular ejection fraction \<35%,
  • the tendency to systemic thrombosis,
  • severe co-morbidities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Karapet Davtyan, PhD

    National Research Center for Preventive Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 24, 2020

First Posted

March 26, 2020

Study Start

September 1, 2015

Primary Completion

December 30, 2017

Study Completion

December 31, 2018

Last Updated

March 26, 2020

Record last verified: 2020-03